It was demonstrated recently that in breast cancer, EzH2 promotes a constitutive activation of NF-κB that leads to an increase in its target genes expression, including IL-8, IL-6 and TNF-α cytokines [24], suggesting that it might be doing the same in our model of CAC. Here, NFKB1 is linked to breast cancer.